Site Sponsors
  • Oxford Instruments Nanoanalysis - X-Max Large Area Analytical EDS SDD
  • Park Systems - Manufacturer of a complete range of AFM solutions
  • Strem Chemicals - Nanomaterials for R&D
Add Company

There is 1 related live offer.

Save 25% on magneTherm

Alnis BioSciences Inc.

626 Bancroft Way #3B
Berkeley
CA, 94710
United States
PH: 1 (510) 845 1641
Email: alnis@alnis.com
Visit Alnis BioSciences Inc. Website or Request Quote for Further Information

Primary Activity

Material Manufacturer

Company Background

Alnis is a drug development company with a potent, enabling therapeutic platform to treat cancer as well as infectious and inflammatory diseases. Alnis has engineered nanoscopic hydrogels, or NanoGels, comprised of polymers, bioactives, and targeting molecules. These NanoGels are intended to selectively target pathological tissues, treat the disease, and afterwards simply disintegrate, returning to the individual components from which they were formed. Throughout this process, the NanoGels are designed to provide the patient with a lower systemic exposure to the toxic effects of bioactive components than previously possible. Additionally, nanogels are designed to improve potency. This combination of better safety and higher efficacy produces a large increase in therapeutic index.

Proprietary NanoGels to treat cancer and infectious diseases are actively under development at Alnis. The Company's first target indications are cancer Ð renal, breast, and liver, in particular, where patients are poorly served by current therapeutics. Solid tumors such as these possess a leaky vasculature that allows chemotherapeutic-rich NanoGels to exit the bloodstream and enter the tumor. The blood vessels of healthy tissues are not leaky, so these particles cannot as easily enter healthy tissue.

Ask A Question

Do you have a question you'd like to ask this Supplier?

Leave your feedback
Submit